Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Abstract from Movement Disorders Conference

June 22, 2016August 16, 2022 Alterity Therapeutics

Abstract from Movement Disorders Conference 2016

2016

Post navigation

Prana’s Huntington Disease trial analysis to feature at global movement disorder conference

Prana Alzheimer’s disease data features at world leading conference

Related Posts

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

August 31, 2023August 31, 2023

Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021

November 9, 2021August 16, 2022

Alterity Therapeutics Raises $3.25 M AUD in Placement

February 23, 2024February 23, 2024

Recent Posts

Alterity to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
XBRL 30 June 2024 filed with the SEC
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065